Biologics Boom vs. Oral Formulations: Is Pharma Facing a Skills Gap?
Over the last few years, the pharmaceutical industry’s capital investment strategy has been undeniably focused on biologics. Spurred by the global demand for COVID-19 vaccines and the acceleration of cell and gene therapies, biologics have attracted the lion’s share of funding, infrastructure and talent development since 2020. From cutting-edge monoclonal antibody treatments to viral vector…